Bebtelovimab Available for Purchase 8/15
Bebtelovimab will be available for purchase from the distributor AmerisourceBergen (ABC) during the week of August 15, 2022.
- The purchase cost per patient course of Bebtelovimab will be $2,100.
- CMS reimbursement cost for the medication for Medicaid and Medicare patients is pending and will be posted here when it is available.
- An ABC account is required to purchase Bebtelovimab. Contact asdaccountsetup@amerisourcebergen.com to set up an ABC account.
- For questions about purchasing Bebtelovimab, contact c19therapies@amerisourcebergen.com.
- ABC will not take returns of purchased Bebtelovimab for refunds.
Distribution of Bebtelovimab that was purchased by the United States government (USG) and distributed to providers through state allocation will end in mid-august. Providers may submit requests for Bebtelovimab in HPOP before 5 pm CT on Friday, August 12, 2022, for the final DSHS allocation.
Facilities must continue to report transfers, wastage, and administration and on-hand inventory of all USG-purchased Bebtelovimab in HPOP until this supply has depleted. Providers MAY NOT seek reimbursement for the Bebtelovimab that was distributed at no cost from USG and should keep this stock separated from any product that is purchased. Read the 8/4 communication for more information.
New Evusheld Helpline for Providers
AstraZeneca has established a helpline to receive additional general product information as well as specific guidance on how to access the product, including information on ordering.
1-833-EVUSHLD (1-833-388-7453)
In addition, ASPR has opened a new route for providers who are not enrolled as a COVID-19 therapeutics provider in HPOP to obtain 1-3 courses of Evusheld for their patients. Providers may request small quantities directly from the manufacturer using this form.
For additional information, see ASPR: New Helpline and Ordering Pathway for Evusheld.
Note: There is a new JAMA Patient Page for Evusheld
Shelf-Life Extensions
Several products have initial expiration dates approaching, but. many COVID-19 therapeutics have received extensions. Please check with the manufacturer before removing any products from the proper storage conditions.
See links below for detailed expiry information:
Also see the FDA’s approach to COVID-19 Therapeutics shelf-life extensions here.
Maintain all monoclonal antibodies under proper refrigerated temperatures, even if they are not currently authorized for use. It is expected that will be authorized again in the future for use against new strains of SARS-COV2.
|
